510(k) device
Medtronic Minimed Paradigm Insulin Pumps
Medtronic Minimed · Pump, Infusion, Insulin (LZG, Class II) · First FDA decision May 21, 2004, newest Mar 29, 2012Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
510(k) pathway
Device trials
22
Naming "Minimed Paradigm"
MAUDE reports
6
Brand "Minimed Paradigm", since 2015
PubMed studies
24
Mentioning "Minimed Paradigm"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Medtronic Minimed Paradigm Insulin Pumps
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
K120206 · Decided Mar 29, 2012 · 66 days after receipt
Device type: Pump, Infusion, Insulin (LZG) · Hospital Medicine & Nursing
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Insulin Infusion PumpNational analysisReview closedCAG-00041NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Minimed Paradigm", any status and sponsor, newest update first.
University of OklahomaAcademic, hospital or other
NCT00582036 · 11 participants · Start Feb 2007 · Primary completion May 2009
Device: Deployment of the MiniMed Paradigm monitoring device · For: Hyperglycemia; Hematopoietic Stem Cell Transplantation
Sites: Oklahoma City, Oklahoma
21 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Minimed Paradigm", and for the whole product code for context.
This brand
6 reports: 1 malfunction, 5 injury, 0 death
Whole product code LZG
385,399 reports: 329,529 malfunction, 55,119 injury, 355 death
Newest reports for this brand
MW5135248 · Received Aug 12, 2023
Device type: Pump, Infusion, Insulin, To Be Used With Invasive Glucose Sensor (OYC)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypoglycemia
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Paradigm Insulin Pump (MMT-712, MMT-715)Open, Classified
Z-1748-2026 · Started Feb 13, 2026 · Posted by FDA Apr 2, 2026
Reason given: All Medtronic MiniMed infusion pumps (Paradigm series, 600 series, and BLE 700 series) were found to be affected by unintended over- and under-delivery of insulin when the pump is elevated or lowered relative to the infusion site, respectively, because of changes in gravitational force impacting hydrostatic and...
Cause as FDA categorized it: Device Design · Device type: Pump, Infusion, Insulin (LZG)
8 more recall records with a free account
Published research
The most relevant PubMed records for "Minimed Paradigm"[tiab]. The summary above synthesizes these.
- Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial.
Lawson ML, Verbeeten KC, Courtney JM, et al. · Pediatr Diabetes · 2021Multicenter Study, Randomized Controlled Trial
- Usability and training differences between two personal insulin pumps.
Schaeffer NE, Parks LJ, Verhoef ET, et al. · J Diabetes Sci Technol · 2015Multicenter Study, Randomized Controlled Trial
- Glycemic Control and Hypoglycemia in Patients Treated with Insulin Pump Therapy: An Observational Study.
Guzmán G, Martínez V, Yara JD, et al. · J Diabetes Res · 2020Observational Study
- Use of continuous glucose monitoring for sport in type 1 diabetes.
Abdulrahman A, Manhas J, Linane H, et al. · BMJ Open Sport Exerc Med · 2018
- Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes.
Zijlstra E, Demissie M, Graungaard T, et al. · J Diabetes Sci Technol · 2018Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The integrated MiniMed Paradigm REAL-Time insulin pump and glucose monitoring system: implications for improved patient outcomes.
Mastrototaro J, Lee S · Diabetes Technol Ther · 2009
- Clinical experience with an integrated continuous glucose sensor/insulin pump platform: a feasibility study.
Mastrototaro JJ, Cooper KW, Soundararajan G, et al. · Adv Ther · 2006
- Insulin bolusing software: the potential to optimize health outcomes in type 1 diabetes mellitus.
Driscoll KA, Johnson SB, Hogan J, et al. · J Diabetes Sci Technol · 2013Research Support, Non-U.S. Gov't
- Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue.
Regittnig W, Urschitz M, Lehki B, et al. · Diabetes Technol Ther · 2019Clinical Trial, Research Support, Non-U.S. Gov't
- Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes.
Calhoun P, Lum J, Beck RW, et al. · Diabetes Technol Ther · 2013Comparative Study, Research Support, Non-U.S. Gov't
- Combined insulin pump therapy with real-time continuous glucose monitoring significantly improves glycemic control compared to multiple daily injection therapy in pump naïve patients with type 1 diabetes; single center pilot study experience.
Lee SW, Sweeney T, Clausen D, et al. · J Diabetes Sci Technol · 2007
- Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.
Borot S, Franc S, Cristante J, et al. · J Diabetes Sci Technol · 2014Clinical Trial, Comparative Study
Other devices of this type
Also filed under product code LZG.
- Omnipod® Insulin Management System, Omnipod DASH® Insulin Management SystemInsulet Corporation · 510(k) 2021
- t:slim Insulin Delivery System, t:flex Insulin Delivery SystemTandem Diabetes Care, Inc. · 510(k) 2016
- Pivot Insulin Delivery SystemModular Medical, Inc. · 510(k) 2026
- Extended ReservoirMedtronic Minimed · 510(k) 2024
- Amigo Insulin PumpNipro Diabetes Systems, Inc. · 510(k) 2007
- Modular Medical MODD1 Insulin Delivery SystemModular Medical, Inc. · 510(k) 2024
- Omnipod GO Insulin Delivery DeviceInsulet Corporation · 510(k) 2023
- Omnipod DASH Insulin Management SystemInsulet Corporation · 510(k) 2018
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.